Research and Markets: Global Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Report - 2015 Pipeline Insights

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/znjm2z/transitional_cell) has announced the addition of the "Transitional Cell Cancer (Urothelial Cell Cancer)-Pipeline Insights" report to their offering.

Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Insights provides the in-depth analysis of the pipeline assets across the Transitional Cell Cancer (Urothelial Cell Cancer). The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The Transitional Cell Cancer (Urothelial Cell Cancer) Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Insights Report covers the Transitional Cell Cancer (Urothelial Cell Cancer) pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also provides Transitional Cell Cancer (Urothelial Cell Cancer) related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. The Report also highlights the discontinued and inactive projects in pipeline for Transitional Cell Cancer (Urothelial Cell Cancer).

Scope

- The report provides a Transitional Cell Cancer (Urothelial Cell Cancer) Landscape across the globe

- The report provides drug profiles which includes product description, MOA, licensors & collaborators, technology, development partner and chemical information

- Coverage of the Transitional Cell Cancer (Urothelial Cell Cancer) pipeline on the basis of target, MOA, route of administration, technology involved and molecule type

- The report reviews key players involved in the therapeutics development for Transitional Cell Cancer (Urothelial Cell Cancer) and also provide company profiling

- Pipeline products coverage based on various stages of development from NDA filings to discovery.

- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

For more information visit http://www.researchandmarkets.com/research/znjm2z/transitional_cell

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals